First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data. (30th July 2018)

• Record Type: Journal Article
• Authors: Sheng, Xinan; Bi, Feng; Ren, Xiubao; Cheng, Ying; Wang, Jinwan; Rosbrook, Brad; Jiang, Ming; Guo, Jun
• Is Part Of: Future oncology. Volume 15:Number 1(2019)
• Page Start: 53
• Page End: 63
• Publication Date: 2018-07-30
• Subjects: Asian patients -- axitinib -- progression-free survival -- renal cell carcinoma; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0442
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: Efficacy/safety of first-line axitinib in Asian patients with metastatic renal cell carcinoma.Methods: Patients were assigned (2:1) to 5-mg axitinib (n = 48) or 400-mg sorafenib (n = 24) twice daily. Primary end point was progression-free survival. Objective response rate, overall survival and adverse events were also assessed.Results: For axitinib versus sorafenib, hazard ratio for progression-free survival was 0.652 (95% CI: 0.340–1.252; p = 0.0989), objective response rate was higher (35.4 vs 16.7%; p = 0.0495), overall survival longer (hazard ratio: 0.739; 95% CI: 0.397–1.375; p = 0.1683). Palmar-plantar erythrodysesthesia (57.4%), diarrhea (55.3%), hypertension (51.1%) were commonest adverse events with axitinib; palmar-plantar erythrodysesthesia (50.0%) with sorafenib.Conclusion: Axitinib improved efficacy in Asian patients with metastatic renal cell carcinoma; adverse events were consistent with previous findings.